SG
NVO

Sankala Group’s Novo Nordisk NVO Stock Holding History

Sankala Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$378K Buy
10,432
+281
+3% +$13.3K 0.31% 73
2025
Q4 		$380K Buy
+10,151
New +$519K 0.3% 77

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Sankala Group's NVO Position: Q1 2026 in Review

Sankala Group increased its Novo Nordisk (NVO) stake by 2.8% in Q1 2026, buying an estimated $13.3K and bringing the position to 10,432 shares worth $378K. The position accounts for 0.31% of the portfolio, ranked #73.

Sankala Group first reported a position in NVO in Q4 2025 and has held it in 2 quarters since. The position peaked at $380K in Q4 2025. 1,276 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Sankala Group held 10,432 shares of Novo Nordisk worth $378K as of Q1 2026.
  • Sankala Group bought 281 Novo Nordisk shares in Q1 2026, an estimated $13.3K.
  • Novo Nordisk made up 0.31% of Sankala Group's portfolio in Q1 2026, its #73 holding.
  • Sankala Group first reported a position in Novo Nordisk in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's Novo Nordisk position peaked at $380K in Q4 2025.
  • 1,276 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.